• PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 3 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 1 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 1 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 1 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…